黃 玲  藥物化學博士  教授  博士生導師

2011年6月畢業于中山大學獲藥物化學博士學位，同年留校任教，2015年1月晉升為副教授，2015年榮獲廣東省“特支計劃”科技創新青年拔尖人才和廣州市珠江科技新星專項人才稱号，2016年赴美國Scripps研究所神經生物學系訪學一年，2018年評為博士生導師。2021年通過高層次人才引進到海南大學工作。

電子郵箱：Linghuang@hainanu.edu.cn

1.教育經曆

2006.09~2011.06：中山大學365英国上市官网在线，博士（碩博連讀）；

2000.09~2004.06：中南大學365英国上市官网在线，本科；

2.科研情況

課題組面向國家重大需求，針對“高效設計和發現神經退行性疾病創新藥物”重大科學難題，結合藥物化學、化學生物學、神經藥理學等理論及實驗技術，長期緻力于神經退行性疾病創新藥物設計與發現研究工作，取得了重要成果，在J. Med. Chem.、Eur. J. Med. Chem.等國際期刊發表 SCI 論文 61 篇，其中第一作者或通訊作者論文39篇（其中中科院大類一區top期刊論文11篇/JCR分區Q1 論文19篇，JCR分區Q2 論文18篇），他引 2000餘次，3篇論文他引超過100次，單篇最高他引 151次，h-index 30。申請中國發明專利15項，已獲授權專利4項。主持國家自然科學基金面上項目，青年科學基金、廣東省自然科學基金等10餘項課題。

3.研究領域

神經退行性疾病創新藥物設計與發現

4.主持的科研項目：

1）海南大學 C 類高層次人才引進經費，300 萬，2021-2025，主持

2）國家自然科學基金面上項目: 新型多靶點抗阿爾茨海默病喹啉衍生物：設計合成、生物活性與分子機制研究，64.0萬元，2018 - 2021，主持

3）廣東省“特支計劃”科技創新青年拔尖人才項目，30.0萬元，2016 - 2019

4）廣州市珠江科技新星專項，30.0萬元，2016 - 2019，主持

5）廣東省自然科學基金面上項目：多靶點抗阿爾茨海默病藥物分子設計合成、活性研究及作用機制探索；10.0萬元，2015-2018，主持

6）中山大學高校基本科研業務費青年教師培育項目：靶向Aβ神經毒性機制網絡的苯并異硒唑酮喹啉衍生物的設計合成及其抗阿爾茨海默病作用研究；15.0萬元， 2015 - 2018，主持

7）國家自然科學基金青年基金：基于多靶點策略的茚酮衍生物的設計合成與抗阿爾茨海默病活性及作用機制研究，25.0萬元，2014 - 2016，主持

5.第一作者或通訊作者論文

1）Jinhui Hu, Tingting Pan, Baijiao An, Zhengcunxiao Li , Xingshu Li*, Huang, Ling*. Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease. Eur. J. Med. Chem., 2019, 512− 526.

2）Jinhui Hu, , Ya-Dan Huang, Tingting Pan, Tianhua Zhang , Tao Su, Xingshu Li , Hai-Bin Luo, * Ling Huang,*. Design, Synthesis, and Biological Evaluation of Dual-Target Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 9A (PDE9A) for the Treatment of Alzheimer's Disease. ACS Chem. Neurosci, 2019, 10, 537−551.

3）Tingting Pan, Shishun Xie, Yan Zhou, Huijin Hu, Haibin Luo, Xingshu Li, Ling Huang *. Dual functional cholinesterase and PDE4D inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of tacrine-pyrazolo [3,4-b] pyridine hybrids. Bioorg. Med. Chem. Lett, 2019, 29 (16), 2150-2152

4）Zhiren Wang, Jinhui Hu, Xiaoping Yang, Xing Feng, Xingshu Li,* Ling Huang,* and Albert S. C. Chan. Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline–Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer’s Disease. J. Med. Chem. 2018, 61, 1871-1894.

5）Baijiao An, Bo Wang, Jinhui Hu, Shaoyu Xu, Ling Huang,* Xingshu Li,* and Albert S. C. Chan. Synthesis and Biological Evaluation of Selenium-Containing 4-Anilinoquinazoline Derivatives as Novel Antimitotic Agents. J. Med. Chem. 2018, 61, 2571-2588.

6）Jinhui Hu, Baijiao An, Tingting Pan, Zhengcunxiao Li, , Huang, Ling*, Xingshu Li. Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease, Bioorg Med Chem, 2018, 26, 5718-5729.

7）Chuan-Jun Lu, Jinhui Hu, Zechen Wang, Shishun Xie, Tingting Pan, LingHuang*, Xingshu Li. Discovery of boron-containing compounds as Aβ aggregationinhibitors and antioxidants for the treatment of Alzheimer's disease, MedChemComm, 2018, 9, 1862-1870.

8）Shun Zhang, Baijiao An, Jiayan Li, Jinhui Hu, Ling Huang,* Xingshu Li * and Albert S. C. Chan. Synthesis and evaluation of selenium-containing indole chalcone and diarylketone derivatives as tubulin polymerization inhibition agents. Org. Biomol. Chem., 2017, 15, 7404 – 7410.

9）Jun Yan, Jie Chen, Shun Zhang, Jinhui Hu, Ling Huang,* and Xingshu Li*. Synthesis, Evaluation, and Mechanism Study of Novel IndoleChalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo. J. Med. Chem. 2016, 59, 5264−5283.

10）Tao Su, Tianhua Zhang, Shishun Xie, JunYan, Yinuo Wu, Xingshu Li, Ling Huang,* and Hai-Bin Luo *. Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer’s disease. Sci. Rep. 2016, (6), 1-14. Zhiren Wang, Wenrui Li, Yali Wang, Xiruo Li, Ling Huang,* Xingshu Li*. Design, synthesis and evaluation of clioquinol-ebselen hybrids as multi-target-directed ligands against Alzheimer's disease. RSC Adv. 2016, 7139-7158.

11）Yali Wang, Yang Sun, Yueyan Guo, Zechen Wang, Ling Huang*, Xingshu Li. Dual functional cholinesterase and MAO inhibitors for the treatment of Alzheimer’s disease: synthesis, pharmacological analysis and molecular modeling of homoisoflavonoid derivatives. J. Enzyme. Inhib. Med. Chem. 2016, 31(3), 389-397.

12）Zhiren Wang, Yali Wang, Bo Wang, Wenrui Li, Ling Huang,* and Xingshu Li*. Design, Synthesis and Evaluation of Orally Available Clioquinol-Moracin M Hybrids as Multi-Target-Directed Ligands for Cognitive Improvement in a Rat Model of Neurodegeneration in Alzheimer’s Disease. J. Med. Chem. 2015, 8616–8637.

13）Zhiren Wang, Yali Wang, Wenrui Li, Zhihong Liu, Zonghua Luo, Yang Sun, Ruibo Wu, Ling Huang,* and Xingshu Li*. Computer-assisted designed “selenoxy–chinolin”: a new catalytic mechanism of the GPx-like cycle and inhibition of metal-free and metal-associated Aβ aggregation. Dalton Trans., 2015, 44, 20913-25.

14）Jun Yan, Yueyan Guo, Yali Wang, Fei Mao, Ling Huang*, ,Xingshu Li *. Design, synthesis, and biological evaluation of benzoselenazole-stilbene hybrids as multi-target-directed anti-cancer agents. Eur. J. Med. Chem. 2015, 95, 220-229.

15）Jun Yan, Yanqing Pang, Jie Chen, Jianfei Sheng, Jinhui Hu, Ling Huang,* and Xingshu Li*. Synthesis, biological evaluation and mechanism study of a class of cyclic combretastatin A-4 analogues as novel antitumour agents. RSC Adv. 2015, 98527-98537.

16）Jie Chen, Jun Yan, Jinhui Hu, Yanqing Pang, Ling Huang*, Xingshu Li*. Synthesis, Biological Evaluation and Mechanism Study of Chalcone Analogues as Novel Anti-cancer Agents. RSC Adv. 2015, 5, 68128-68135.

17）Shishun Xie, Jie Chen, Xiruo Li, Tao Su, Yali Wang, Zhiren Wang, Ling Huang*, Xingshu Li*. Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease. Bioorg. Med. Chem., 2015, 23, 3722–3729.

18）Jinhui Hu, Jun Yan, Jie Chen, Yangqing Pan, Ling Huang*, ,Xingshu Li *.Synthesis, biological evaluation and mechanism study of a class of benzylideneindanone derivatives as novel anticancer agents. MedChemComm., 2015,6, 318-1327.

19）Tao Su, Shishun Xie, Bifu Li, Jun Yan, Ling Huang,* Xingshu Li*. Copper-catalyzed three-component one-pot synthesis of substituted 2-aryl-1,3-benzoselenazoles. Synlett. 2015, 26, 215-220.

20）Fei Mao, Jianheng Li, Hui Wei, Ling Huang,* Xingshu Li*. Tacrine–propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer’s disease. J. Enzyme. Inhib. Med. Chem. 2015, 995-1001. Zhiren Wang , Yali Wang, Wenrui Li, Fei Mao, Yang Sun, Ling Huang*, ,Xingshu Li *. Design, synthesis, and evaluation of multitarget-directed selenium-containing clioquinol derivatives for the treatment of Alzheimer's disease. ACS Chem. Neurosci. 2014, 5, 952− 962.

21）Jianfei Sheng, Fei Mao, Jun Yan , Ling Huang *, Xingshu Li*.The convenient aqueous synthesis and biological evaluation of ortho-(3,4,5-trimethoxybenzoyl)-acetanilides as novel anti-cancer agents. RSC Adv., 2014, 4, 41510 - 41520. Ling Huang, Hui Miao, Yang Sun, Fanchao Meng, Xingshu Li*. Discovery of indanone derivatives as multi-target-directed ligands against Alzheime r's disease. Eur. J. Med. Chem. 2014, 87, 429 - 439. Ling Huang, Wenjun Shan, Qi Zhou, Jiaxing Xie, Kefang Lai, Xingshu Li*. Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors. Bioorg. Med. Chem. Lett. 2014, 24, 249–253.Fei Mao, Jun Yan, Jianheng Li, Xian Jia, Hui Miao, Yang Sun, Ling Huang* , Xingshu Li*. New multi-target-directed small molecules against Alzheimer ’ s disease: a combination of resveratrol and clioquinol. Org. Biomol. Chem., 2014, 12, 5936 –5944.

22）Chuanjun Lu, Yueyan Guo, Jun Yan, Zonghua Luo, Hai-Bin Luo, Ming Yan, Ling Huang*, Xingshu Li*. Design, Synthesis, and Evaluation of Multitarget-Directed Resveratrol Derivatives for the Treatment of Alzheimer's Disease. J. Med. Chem. 2013, 56(14), 5843−5859

23）Zonghua Luo , Jianfei Sheng, Yang Sun, Chuanjun Lu, Jun Yan, Anqiu Liu, Hai-Bin Luo, Ling Huang*, Xingshu Li*. Synthesis and evaluation of multi-target-directed ligands against Alzheimer’s disease based on the fusion of donepezil and ebselen. J. Med. Chem. 2013, 56, 9089− 9099.

24）Ling Huang, Tao Su, Xingshu.Li*. Natural Products as Sources of New Lead Compounds for the Treatment of Alzheimer's Disease. Curr. Top. Med. Chem. 2013, 13(15), 1864-1878.

25）Chuanjun Lu , Qi Zhou, Jun Yan, Zhiyun Du, Ling Huang*, Xingshu Li*. A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer’s disease. Eur. J. Med. Chem. 2013, 62, 745-753.

26）Tao Su, Shishun Xie, Hui Wei, Jun Yan, Ling Huang*, Xingshu Li*.Synthesis and biological evaluation of berberine–thiophenyl hybrids as multi-functional agents: Inhibition of acetylcholinesterase, butyrylcholinesterase, and Aβ aggregation and antioxidant activity. Bioorg. Med. Chem. 2013, 21(18), 5830–5840.

27）Ling Huang, Chuanjun Lu, Yang Sun, Fei Mao, Zonghua Luo, Tao Su, Huailei Jiang, Wenjun Shan, Xingshu Li*. Multitarget-Directed Benzylideneindanone Derivatives: Anti-β-Amyloid (Aβ) Aggregation, Antioxidant, Metal Chelation, and Monoamine Oxidase B (MAO-B) Inhibition Properties against Alzheimer’s Disease. J. Med. Chem. 2012, 55(19), 8483− 8492.

28）Yang Sun, Jianwen Chen, Xuemin Chen, Ling Huang*, Xingshu Li*. Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine–Homoisoflavonoid hybrids. Bioorg. Med. Chem. 2013, 21(23), 7406–7417.

29）Ling Huang, Su Tao, Wenjun Shan, Zonghua Luo, Yang Sun and Xingshu Li*. Inhibition of Cholinesterase activity and Amyloid aggregation by Berberine- phenyl-benzoheterocyclic and Tacrine-phenyl-benzoheterocyclic hybrids. Bioorg. Med. Chem. 2012, 20(9), 3038-3048.

30）Meng, Fan-Chao, Mao, Fei; Shan, Wen-Jun; Qin, Fangfei; Huang, Ling*, Li Xing-Shu*. Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents, Bioorg. Med. Chem. Lett., 2012, 22(13), 4462–4466.

課題組長期招聘藥物化學，藥理學，有機化學，生物學等相關專業的研究員、博士後。

歡迎具有藥學、化學、生物學背景的同學報考本課題組研究生。